Close
Nordic 9Nordic 9

Michael Polansky (investor - Angel Investor)

United States
See something wrong or missing? Let us know
Offices:New York

Michael Polansky is CEO of The Parker Group and Co-founder of Parker Institute for Cancer Immunology.

Average round investment:3.5M USD
Average number per year:1.0
Distribution: 2021 (1)
Portfolio companies: United Kingdom Overwatch Research
Mostly invests in: United Kingdom United Kingdom (1) Biotech (1)

1 tracked investments in:

You need an account to access this feature. Log in or create one from here.

Do you have a question? Talk to us.

Investors with similar profile to Michael Polansky

Name Criteria
United Kingdom Bruce Berkeley
92%
  • Range for average deal size: 1M - 5M USD
  • Similar verticals: Biotech, Health services, Software Services
  • Similar business models: B2B, SAAS
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
United Kingdom XTX Ventures
92%
  • Range for average deal size: 1M - 5M USD
  • Similar verticals: Biotech, Health services, Software Services
  • Similar business models: B2B, SAAS
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
United States Robert Fenton
92%
  • Range for average deal size: 1M - 5M USD
  • Similar verticals: Biotech, Health services, Software Services
  • Similar business models: B2B, SAAS
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Israel Nadav Rosenberg
92%
  • Range for average deal size: 1M - 5M USD
  • Similar verticals: Biotech, Health services, Software Services
  • Similar business models: B2B, SAAS
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
United Kingdom Calculus Capital
92%
  • Range for average deal size: 1M - 5M USD
  • Similar verticals: Biotech, Health services, Software Services
  • Similar business models: B2B, SAAS
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.3
  • Active last 12 months: Yes
United States January Ventures
90%
  • Range for average deal size: 1M - 5M USD
  • Similar verticals: Biotech, Health services, Software Services
  • Similar business models: B2B, SAAS
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.5
  • Active last 12 months: Yes
Switzerland Swiss Health Angels
90%
  • Range for average deal size: 1M - 5M USD
  • Similar verticals: Biotech, Health services, Software Services
  • Similar business models: B2B, SAAS
  • Common investees countries: United Kingdom
  • Average number of deals per year: 2.0
  • Active last 12 months: Yes
United Kingdom North East Venture Fund
90%
  • Range for average deal size: 1M - 5M USD
  • Similar verticals: Biotech, Health services, Software Services
  • Similar business models: B2B, SAAS
  • Common investees countries: United Kingdom
  • Average number of deals per year: 2.0
  • Active last 12 months: Yes
United Kingdom o2h Ventures
90%
  • Range for average deal size: 1M - 5M USD
  • Similar verticals: Biotech, Health services, Software Services
  • Similar business models: B2B, SAAS
  • Common investees countries: United Kingdom
  • Average number of deals per year: 2.0
  • Active last 12 months: Yes
United States AME Cloud Ventures
89%
  • Range for average deal size: 1M - 5M USD
  • Similar verticals: Biotech, Health services, Software Services
  • Similar business models: B2B, SAAS
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Top